Cargando…

Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer

Metabolic inhibition via PFKFB3 inhibition has demonstrated considerable tumor inhibitory effects in various studies; however, PFKFB3 inhibition did not show satisfactory tumor inhibition when used in clinical trials. PFKFB3 is a crucial metabolic enzyme that is highly upregulated in cancer cells an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Jia Bo, Wong, Chau Wei, Liu, Jia, Luo, Xiao-Jing, Zhou, Wei-Yi, Chen, Yan-Xing, Luo, Hui-Yan, Zeng, Zhao-Lei, Ren, Chao, Xie, Xiao-Ming, Wang, De-Shen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9191911/ https://www.ncbi.nlm.nih.gov/pubmed/35707221 http://dx.doi.org/10.1080/2162402X.2022.2079182

Ejemplares similares

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma
por: Yu, Bo, et al.
Publicado: (2022)

Glucose and Palmitate Differentially Regulate PFKFB3/iPFK2 and Inflammatory Responses in Mouse Intestinal Epithelial Cells
por: Botchlett, Rachel, et al.
Publicado: (2016)

Digalloyl Glycoside: A Potential Inhibitor of Trypanosomal PFK from Euphorbia abyssinica J.F. Gmel
por: El-Hawary, Seham S., et al.
Publicado: (2022)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

PCK1 Deficiency Shortens the Replicative Lifespan of Saccharomyces cerevisiae through Upregulation of PFK1
por: Yuan, Yuan, et al.
Publicado: (2020)

PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer
por: Zhu, Wei, et al.
Publicado: (2016)

The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb
por: Lu, Panpan, et al.
Publicado: (2016)

Gut microbial structural variation associates with immune checkpoint inhibitor response
por: Liu, Rong, et al.
Publicado: (2023)

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
por: Mondal, Susmita, et al.
Publicado: (2018)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

Rewiring of embryonic glucose metabolism via suppression of PFK-1 and aldolase during mouse chorioallantoic branching
por: Miyazawa, Hidenobu, et al.
Publicado: (2017)

Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course
por: Jiang, Mengjie, et al.
Publicado: (2022)

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
por: Xing, Hui, et al.
Publicado: (2023)

Molecular surveillance of pfcrt, pfmdr1 and pfk13-propeller mutations in Plasmodium falciparum isolates imported from Africa to China
por: Huang, Fang, et al.
Publicado: (2021)

What exactly does the PfK13 C580Y mutation in Plasmodium falciparum influence?
por: Si, Wenwen, et al.
Publicado: (2023)

The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Hu, Da-Hai, et al.
Publicado: (2022)

GFAT and PFK genes show contrasting regulation of chitin metabolism in Nilaparvata lugens
por: Xu, Cai-Di, et al.
Publicado: (2021)

Synthesis of Glycolysis Inhibitor PFK15 and Its Synergistic Action with an Approved Multikinase Antiangiogenic Drug on Human Endothelial Cell Migration and Proliferation
por: Zlacká, Jana, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Zou, Xue-lin, et al.
Publicado: (2021)

Novel pfk13 polymorphisms in Plasmodium falciparum population in Ghana
por: Matrevi, Sena Adzoa, et al.
Publicado: (2022)

PFK15, a PFKFB3 antagonist, inhibits autophagy and proliferation in rhabdomyosarcoma cells
por: Wang, Chunhui, et al.
Publicado: (2018)

Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma
por: Peng, Lijun, et al.
Publicado: (2022)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
por: Zou, Xue-lin, et al.
Publicado: (2021)

Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy
por: Luo, Meng-Chao, et al.
Publicado: (2023)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
por: Liu, Jia, et al.
Publicado: (2022)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
por: Li, Jinpeng, et al.
Publicado: (2023)

TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas
por: Maddalena, Francesca, et al.
Publicado: (2020)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
por: Xiao, Yan, et al.
Publicado: (2020)

Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy
por: Pan, Yi-Hui, et al.
Publicado: (2021)

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis
por: Hu, Jiexuan, et al.
Publicado: (2021)

Prevalence of pfk13 and pfmdr1 polymorphisms in Bounkiling, Southern Senegal
por: Ahouidi, Ambroise, et al.
Publicado: (2021)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
por: Pan, Xian, et al.
Publicado: (2023)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

ENPEP as a potential predictor of immune checkpoint inhibitor efficacy
por: Wang, Aoyun, et al.
Publicado: (2021)

Therapeutic potential of DNA methyltransferase inhibitors with immune checkpoint inhibitor therapy in breast cancer
por: Luo, Na, et al.
Publicado: (2018)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
por: Zhang, Zhen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kjk8olivmj7ku7fc5bi831cned